StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)

Close on Nov 17, 2026Market cap $1.78BP/E –Yield –

Agios Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Agios Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $356.75M, up 11.5% year over year. For fiscal 2025 it was $339.54M, up 12.7% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $341.32M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$339.54M+12.7%
FY2024Dec 31, 2024$301.29M+1.9%
FY2023Dec 31, 2023$295.53M+5.6%
FY2022Dec 31, 2022$279.91M+8.9%
FY2021Dec 31, 2021$256.97M+16.4%
FY2020Dec 31, 2020$220.81M+3.1%
FY2019Dec 31, 2019$214.26M-37.2%
FY2018Dec 31, 2018$341.32M+16.6%
FY2017Dec 31, 2017$292.68M+32.9%
FY2016Dec 31, 2016$220.16M+55.2%
FY2015Dec 31, 2015$141.83M+41.3%
FY2014Dec 31, 2014$100.37M+84.2%
FY2013Dec 31, 2013$54.50M+32.8%
FY2012Dec 31, 2012$41.04M+31.3%
FY2011Dec 31, 2011$31.25M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$100.75M+9.6%
Q1 FY2026Mar 31, 2026$81.15M+11.6%
Q4 FY2025Dec 31, 2025$88.06M+6.3%
Q3 FY2025Sep 30, 2025$86.80M+19.8%
Q2 FY2025Jun 30, 2025$91.94M+18.8%
Q1 FY2025Mar 31, 2025$72.74M+6.0%
Q4 FY2024Dec 31, 2024$82.81M+6.9%
Q3 FY2024Sep 30, 2024$72.46M-11.5%
Q2 FY2024Jun 30, 2024$77.40M+12.3%
Q1 FY2024Mar 31, 2024$68.62M+2.0%
Q4 FY2023Dec 31, 2023$77.49M+10.2%
Q3 FY2023Sep 30, 2023$81.84M+26.0%
Q2 FY2023Jun 30, 2023$68.90M-7.6%
Q1 FY2023Mar 31, 2023$67.30M-4.0%
Q4 FY2022Dec 31, 2022$70.30M-4.1%
Q3 FY2022Sep 30, 2022$64.97M+1.5%
Q2 FY2022Jun 30, 2022$74.52M+20.2%
Q1 FY2022Mar 31, 2022$70.12M+21.6%
Q4 FY2021Dec 31, 2021$73.30M+23.4%
Q3 FY2021Sep 30, 2021$64.00M+23.2%
Q2 FY2021Jun 30, 2021$62.01M+14.6%
Q1 FY2021Mar 31, 2021$57.67M+4.2%
Q4 FY2020Dec 31, 2020$59.42M-44.1%
Q3 FY2020Sep 30, 2020$51.94M-48.9%
Q2 FY2020Jun 30, 2020$54.09M-49.6%
Q1 FY2020Mar 31, 2020$55.36M-42.1%
Q4 FY2019Dec 31, 2019$106.25M+13.3%
Q3 FY2019Sep 30, 2019$101.67M+23.1%
Q2 FY2019Jun 30, 2019$107.39M+23.8%
Q1 FY2019Mar 31, 2019$95.59M+22.2%
Q4 FY2018Dec 31, 2018$93.81M+21.5%
Q3 FY2018Sep 30, 2018$82.56M+13.2%
Q2 FY2018Jun 30, 2018$86.73M+8.7%
Q1 FY2018Mar 31, 2018$78.22M+24.7%
Q4 FY2017Dec 31, 2017$77.22M+19.4%
Q3 FY2017Sep 30, 2017$72.92M+20.2%
Q2 FY2017Jun 30, 2017$79.82M–
Q1 FY2017Mar 31, 2017$62.73M–
Q4 FY2016Dec 31, 2016$64.68M–
Q3 FY2016Sep 30, 2016$60.64M–

More Agios Pharmaceuticals figures

See a number that looks wrong?